ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of Yvonne Chen, PhD, and Antoni Ribas, MD, PhD, both from University of California, Los Angeles, and Gideon Gross, PhD, from the MIGAL-Galilee Research Institute.